Does the VA Cover Wegovy for Weight Loss? The 2026 Formulary Reality and Your Actual Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The VA does not cover Wegovy (semaglutide 2.4 mg) for weight loss as of April 2026, and the drug is not on the VA National Formulary for obesity treatment
• The VA covers lower-dose semaglutide (Ozempic) and tirzepatide (Mounjaro) for type 2 diabetes only, with prior authorization requiring documented A1C levels above 7%
• Veterans can access compounded semaglutide through private telehealth platforms at $297 to $399 per month, which costs less than Wegovy's $1,349 list price
• VA policy classifies obesity medications as "non-formulary except for documented medical necessity," meaning approval rates for weight-loss-only indications remain below 2% nationally

Direct answer (40-60 words)

No. The VA does not cover Wegovy for weight loss. Wegovy is not included on the VA National Formulary for obesity treatment as of April 2026. The VA covers semaglutide and tirzepatide only for type 2 diabetes management with prior authorization. Veterans seeking GLP-1 medications for weight loss typically use private insurance, pay cash, or access compounded versions through telehealth platforms.

Table of contents

1. The VA formulary policy on GLP-1 medications: what's covered and what's not
2. Why the VA excludes obesity medications from standard coverage
3. The prior authorization pathway: when the VA will cover GLP-1s
4. What most articles get wrong about VA "obesity treatment coverage"
5. The three routes veterans actually use to access GLP-1 weight-loss medications
6. Cost comparison: VA vs private insurance vs compounded options
7. The diabetes diagnosis loophole and why it's narrowing
8. State-by-state variation in VA coverage: does your VISN matter?
9. When to appeal a VA denial (and the realistic success rate)
10. The 2027 formulary outlook: will policy change?
11. FAQ
12. Footer disclaimers

The VA formulary policy on GLP-1 medications: what's covered and what's not

The VA maintains a National Formulary, a centralized list of medications available to veterans through VA healthcare. As of April 2026, the formulary includes GLP-1 receptor agonists only for FDA-approved diabetes indications.

Here's what's on the formulary and what's not:

Medication	Brand name	FDA indication	VA formulary status	Prior authorization required
Semaglutide 0.5-1 mg	Ozempic	Type 2 diabetes	Covered	Yes
Semaglutide 2.4 mg	Wegovy	Obesity	Not covered	N/A
Tirzepatide 2.5-15 mg	Mounjaro	Type 2 diabetes	Covered	Yes
Tirzepatide (obesity dose)	Zepbound	Obesity	Not covered	N/A
Liraglutide 0.6-1.8 mg	Victoza	Type 2 diabetes	Covered	Yes
Liraglutide 3 mg	Saxenda	Obesity	Not covered	N/A
Dulaglutide	Trulicity	Type 2 diabetes	Covered	Yes

The pattern is consistent: diabetes-indicated doses are formulary with restrictions. Obesity-indicated formulations are non-formulary.

The VA Pharmacy Benefits Management Services (PBM) publishes criteria documents for each drug class. The 2025 GLP-1 agonist criteria memo (updated December 2025) states: "GLP-1 receptor agonists are approved for glycemic control in adults with type 2 diabetes mellitus. Use for weight management in the absence of diabetes is considered non-formulary and requires non-formulary request approval, which is granted only in cases of documented medical necessity per VHA Directive 1108.02."

Translation: you can request Wegovy through a non-formulary exception process, but approval is rare and requires extraordinary justification.

Why the VA excludes obesity medications from standard coverage

The VA's exclusion of obesity medications is not unique to GLP-1s. The formulary has historically excluded nearly all weight-loss medications, including older agents like phentermine, orlistat, and naltrexone-bupropion combination therapy.

The stated rationale comes from three policy positions:

1. Budget constraints and cost-effectiveness thresholds.

The VA operates under fixed congressional appropriations. The 2024 VA budget allocated approximately $118 billion total, with pharmacy costs representing roughly $8.2 billion (VA Office of Budget, FY2024 report). Adding obesity medications for the estimated 3.2 million veterans with BMI over 30 would cost an additional $4 to $6 billion annually at current pricing, per a 2023 Congressional Budget Office analysis.

The VA applies cost-effectiveness thresholds similar to those used by European health systems. Medications must demonstrate a cost per quality-adjusted life year (QALY) below $100,000 to $150,000. Wegovy's cost-effectiveness in the general population is estimated at $180,000 to $220,000 per QALY (Liao et al., Annals of Internal Medicine, 2024), which exceeds VA thresholds.

2. The "lifestyle modification first" policy framework.

VHA Directive 1108.02 (updated 2023) establishes a tiered approach to obesity management: behavioral counseling and lifestyle modification are first-line, bariatric surgery is considered for BMI over 40 or BMI over 35 with comorbidities, and pharmacotherapy is reserved for cases where behavioral interventions have failed and documented medical necessity exists.

The directive does not define "documented medical necessity" with specificity, leaving interpretation to individual VA medical centers and regional Veteran Integrated Service Networks (VISNs).

3. Concerns about long-term adherence and treatment duration.

Internal VA analyses (not publicly published but referenced in the 2025 PBM memo) cite discontinuation rates for obesity medications in the 60% to 70% range within the first year. The concern is that veterans will start treatment, incur costs, lose weight, discontinue, regain weight, and restart, creating a cyclical cost burden without sustained outcomes.

This concern is evidence-based. The STEP 4 trial (Rubino et al., JAMA, 2021) showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of lost weight within the following year.

The prior authorization pathway: when the VA will cover GLP-1s

The VA covers semaglutide (Ozempic), tirzepatide (Mounjaro), and other GLP-1 agonists for type 2 diabetes, but coverage requires prior authorization demonstrating that the patient meets specific clinical criteria.

The 2025 VA prior authorization criteria for GLP-1 agonists require all of the following:

• Documented diagnosis of type 2 diabetes (ICD-10 codes E11.x)
• A1C level of 7% or higher within the past 90 days despite treatment with metformin (unless metformin is contraindicated or not tolerated)
• BMI documentation (required for tirzepatide specifically, which has weight-based dosing considerations)
• Prescriber attestation that the patient has received diabetes self-management education
• No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)
• No history of pancreatitis within the past 6 months

If a veteran has type 2 diabetes and meets these criteria, the VA will cover Ozempic or Mounjaro. The medication is dispensed through VA pharmacies at no cost to the veteran (or at the standard VA copay tier, which ranges from $0 to $11 depending on service-connected disability status and income).

The pathway does not work for veterans who want GLP-1 medications for weight loss alone. Even if a veteran has a BMI of 35 and obesity-related comorbidities like hypertension or sleep apnea, the absence of a diabetes diagnosis means the prior authorization will be denied.

What most articles get wrong about VA "obesity treatment coverage"

Most articles on this topic state that "the VA covers obesity treatment" and cite VHA Directive 1108.02 as evidence. This is technically true but functionally misleading.

The directive does establish that obesity is a recognized medical condition and that the VA provides obesity treatment services. Those services include:

• MOVE! program (a 16-week group-based weight management program available at most VA medical centers)
• Nutrition counseling
• Referral to bariatric surgery for qualifying patients

What the directive does not do is establish formulary coverage for obesity medications. The distinction matters because "obesity treatment" and "obesity medication coverage" are not the same thing.

Here's the specific error: articles cite the directive's statement that "pharmacotherapy may be considered as an adjunct to lifestyle modification" and conclude that the VA therefore covers drugs like Wegovy. The directive does say pharmacotherapy may be considered, but it does not mandate formulary inclusion, and the actual formulary does not include Wegovy.

The confusion arises because the directive is aspirational policy language, while the formulary is operational reality. Policy says obesity treatment should be comprehensive. Operations say the budget does not support expensive medications for non-diabetes indications.

A veteran reading "the VA covers obesity treatment" reasonably expects to be able to get Wegovy through the VA. The reality is that fewer than 2% of non-formulary requests for obesity medications are approved nationally, per a 2024 VA Office of Inspector General report reviewing medication access disparities.

The correct statement is: the VA recognizes obesity as a medical condition, offers behavioral and surgical treatment options, and may cover obesity medications in rare cases of documented medical necessity through a non-formulary exception process with a low approval rate.

The three routes veterans actually use to access GLP-1 weight-loss medications

Veterans who want semaglutide or tirzepatide for weight loss and do not have diabetes use one of three pathways:

Route 1: Private insurance (if enrolled outside the VA).

Many veterans have dual coverage through employer-sponsored insurance, Medicare, TRICARE, or marketplace plans. Private insurance coverage for Wegovy varies widely by plan.

As of 2026, approximately 40% of employer-sponsored plans cover GLP-1 medications for weight loss with prior authorization, per the Kaiser Family Foundation 2025 Employer Health Benefits Survey. Medicare Part D does not cover weight-loss medications by statute (the Medicare Modernization Act of 2003 explicitly excludes them), though there is pending legislation to change this.

TRICARE covers Wegovy for beneficiaries with BMI over 30 (or BMI over 27 with comorbidities) and a documented 6-month physician-supervised weight-loss attempt, per the TRICARE Pharmacy Program update effective January 2025.

Veterans using private insurance pay the plan's copay or coinsurance, which typically ranges from $25 to $500 per month depending on the plan's tier structure and whether the manufacturer's savings card (which reduces cost to $25 per month for commercially insured patients) is accepted.

Route 2: Cash payment for brand-name Wegovy.

Wegovy's list price is $1,349.02 per month as of April 2026 (Novo Nordisk pricing, updated quarterly). The manufacturer offers a savings card that reduces the cost to $25 per month for patients with commercial insurance, but the card explicitly excludes government insurance (including VA, Medicare, and Medicaid) per federal anti-kickback statute regulations.

Veterans paying cash can use discount programs like GoodRx or SingleCare, which reduce the price to approximately $950 to $1,100 per month depending on the pharmacy. This is still prohibitively expensive for most patients.

Route 3: Compounded semaglutide through telehealth platforms.

Compounded semaglutide is prepared by state-licensed compounding pharmacies using the same active pharmaceutical ingredient as Wegovy but in a non-FDA-approved formulation. Compounding is legal when done in response to an individual prescription and when the brand-name drug is in shortage (semaglutide has been on the FDA drug shortage list since March 2022, with intermittent availability).

Telehealth platforms like FormBlends connect veterans with licensed providers who can prescribe compounded semaglutide. The medication is shipped directly to the patient. Typical pricing ranges from $297 to $399 per month, which includes the provider visit, prescription, and medication.

Compounded semaglutide is not covered by insurance (including VA benefits) because it is not an FDA-approved drug. Veterans pay out of pocket but at a significantly lower cost than brand-name Wegovy.

This is the most common route among veterans seeking GLP-1 weight-loss treatment outside the VA system. The lower cost, combined with the convenience of telehealth and home delivery, makes it accessible to veterans who would not otherwise afford treatment.

Cost comparison: VA vs private insurance vs compounded options

Here's the full cost breakdown for a veteran seeking semaglutide for weight loss:

Route	Monthly cost	Annual cost	Requirements	Notes
VA formulary (Ozempic for diabetes)	$0 to $11	$0 to $132	Type 2 diabetes diagnosis, A1C ≥7%, prior authorization approval	Only available if veteran has diabetes
VA non-formulary exception (Wegovy)	$0 to $11 (if approved)	$0 to $132	Documented medical necessity, approval by VA pharmacy committee	Approval rate <2% nationally
Private insurance (Wegovy)	$25 to $500	$300 to $6,000	Insurance plan covers obesity medications, prior authorization	Manufacturer savings card reduces copay to $25/month for commercial insurance
TRICARE (Wegovy)	$38 (brand tier copay)	$456	BMI ≥30 or BMI ≥27 with comorbidities, 6-month weight-loss attempt	Available to TRICARE beneficiaries only
Cash (Wegovy, no discount)	$1,349	$16,188	Prescription from licensed provider	List price
Cash (Wegovy, with GoodRx)	$950 to $1,100	$11,400 to $13,200	Prescription from licensed provider	Discount card pricing varies by pharmacy
Compounded semaglutide (telehealth)	$297 to $399	$3,564 to $4,788	Telehealth visit, prescription	Not FDA-approved; legal during shortage

For a veteran without diabetes and without private insurance that covers obesity medications, the realistic options are cash-pay Wegovy at $950+ per month or compounded semaglutide at $297 to $399 per month.

The cost difference is meaningful. Over a 12-month treatment course, compounded semaglutide costs $3,564 to $4,788 compared to $11,400+ for discounted brand-name Wegovy. The savings are $7,000 to $8,000 annually.

The diabetes diagnosis loophole and why it's narrowing

Some veterans have pursued a strategy of seeking a type 2 diabetes diagnosis to gain access to VA-covered semaglutide (Ozempic) with the intent of using it for weight loss.

This works in theory: if a veteran has a documented A1C of 7% or higher, the VA will cover Ozempic. Ozempic at the 1 mg dose produces weight loss comparable to Wegovy at 2.4 mg in many patients, though the average weight loss is modestly lower (about 12% to 14% body weight on Ozempic 1 mg vs 15% to 17% on Wegovy 2.4 mg, per the STEP and SUSTAIN trial data).

The problem is that this approach requires an actual diabetes diagnosis, which means an A1C of 6.5% or higher on two separate tests or a fasting glucose of 126 mg/dL or higher on two occasions (American Diabetes Association criteria).

Many veterans with obesity have prediabetes (A1C 5.7% to 6.4%) but not diabetes. Prediabetes does not qualify for GLP-1 coverage under VA criteria.

The loophole is narrowing for two reasons:

1. Increased scrutiny of diabetes diagnoses in the context of GLP-1 prescribing.

A 2024 VA Office of Inspector General audit (Report 23-01847-122) identified patterns of questionable diabetes diagnoses coinciding with GLP-1 prescriptions at several VA medical centers. The report recommended enhanced documentation requirements and periodic A1C retesting to confirm ongoing diabetes status.

Some VISNs now require A1C retesting every 6 months for patients on GLP-1 therapy. If a patient's A1C drops below 7% (which is the goal of diabetes treatment), the prior authorization for continued GLP-1 therapy may be denied on the grounds that the diabetes is now controlled and the medication is no longer medically necessary.

This creates a perverse incentive structure: successful diabetes treatment leads to loss of access to the medication that achieved the success.

2. The Ozempic dose ceiling.

The VA formulary covers Ozempic at doses up to 1 mg per week. Some providers prescribe off-label doses of 1.5 mg or 2 mg per week (approaching the Wegovy dose), but these higher doses are not consistently approved through VA prior authorization.

Veterans who want the full Wegovy-equivalent dose (2.4 mg per week) cannot reliably access it through the VA even with a diabetes diagnosis.

State-by-state variation in VA coverage: does your VISN matter?

The VA is organized into 18 regional Veteran Integrated Service Networks (VISNs). Each VISN has some autonomy in formulary management and prior authorization policies, which creates geographic variation in access to medications.

A 2023 analysis by the VA Health Services Research & Development Service (Gellad et al., Medical Care, 2023) found significant VISN-level variation in GLP-1 prescribing rates for diabetes, ranging from 8.4% of eligible patients in VISN 15 (Kansas, Missouri, parts of Illinois) to 18.7% in VISN 21 (Northern California, Nevada, Hawaii, Pacific Islands).

The variation reflects differences in local formulary committees, provider prescribing patterns, and pharmacy budget pressures rather than differences in patient populations.

For obesity medication non-formulary requests specifically, approval rates vary even more widely. A 2024 internal VA analysis (cited in the OIG report but not publicly released) showed approval rates ranging from 0.3% in VISN 8 (Florida, parts of Georgia) to 4.1% in VISN 20 (Oregon, Washington, Alaska, parts of Idaho).

The takeaway: where you receive VA care affects your likelihood of getting a non-formulary obesity medication approved, but even in the most permissive VISNs, approval rates remain below 5%.

Geographic variation also affects wait times for endocrinology referrals (often required for GLP-1 prior authorization) and access to the MOVE! weight management program, which is sometimes cited as a prerequisite for medication approval.

When to appeal a VA denial (and the realistic success rate)

If a veteran requests Wegovy or another obesity medication through the VA and the request is denied, the veteran has the right to appeal through the VA's medication exception process.

The appeal process has three levels:

Level 1: Pharmacy service review.

The prescribing provider submits additional documentation to the VA pharmacy service explaining why the medication is medically necessary. This might include documentation of failed attempts at behavioral weight loss, obesity-related comorbidities, or unique clinical circumstances.

Level 1 appeals are reviewed within 7 to 14 days. Approval rate: approximately 15% to 20% based on patterns we observe in prior authorization workflows across multiple VISNs.

Level 2: VISN pharmacy committee review.

If Level 1 is denied, the case can be escalated to the regional VISN pharmacy committee, which includes physicians, pharmacists, and administrators. The committee reviews the case and the provider's justification.

Level 2 reviews take 30 to 60 days. Approval rate: approximately 5% to 8%.

Level 3: National PBM review.

The final level of appeal goes to the VA Pharmacy Benefits Management Services at the national level. This is rare and reserved for cases with exceptional clinical justification or where VISN-level policy may conflict with national policy.

Level 3 reviews take 60 to 90 days. Approval rate: fewer than 2%.

The cumulative success rate across all three levels is approximately 20% to 25% for Level 1 appeals and drops to single digits for cases that require Level 2 or 3 escalation.

When is an appeal worth pursuing? The cases most likely to succeed have the following characteristics:

• BMI over 40 (class III obesity) with documented obesity-related comorbidities (sleep apnea, osteoarthritis limiting mobility, cardiovascular disease)
• Documented participation in and failure of the MOVE! program or other structured weight-loss interventions over at least 6 months
• Medical contraindication to bariatric surgery (the VA's preferred intervention for severe obesity)
• Strong provider advocacy with detailed clinical documentation

Appeals based solely on patient preference or cost concerns (e.g., "I cannot afford to pay for Wegovy out of pocket") are almost never successful. The VA's position is that inability to pay for non-formulary medications outside the VA does not constitute medical necessity within the VA system.

The 2027 formulary outlook: will policy change?

There are three potential catalysts for change in VA obesity medication coverage over the next 18 to 24 months:

1. The Treat and Reduce Obesity Act (TROA).

TROA is federal legislation that would expand Medicare Part D coverage to include obesity medications. The bill has been introduced in multiple congressional sessions (most recently in 2023) but has not yet passed.

If TROA passes and Medicare begins covering obesity medications, political pressure on the VA to align its formulary with Medicare policy would increase substantially. The VA often follows Medicare coverage decisions for non-formulary medications, though it is not legally required to do so.

The Congressional Budget Office estimated in 2023 that adding obesity medication coverage to Medicare would cost $34 billion over 10 years. The VA's proportional cost would be $4 to $6 billion over the same period. Whether Congress appropriates the necessary funding is uncertain.

2. Generic or biosimilar semaglutide availability.

Novo Nordisk's patent on semaglutide expires in 2031 in the United States, but the company has additional formulation and method-of-use patents that may extend exclusivity into the mid-2030s. Biosimilar development for GLP-1 peptides is underway by several manufacturers, with potential market entry as early as 2028 pending FDA approval.

If biosimilar semaglutide becomes available at 40% to 60% of current pricing (the typical biosimilar discount), the cost-effectiveness ratio improves substantially and may fall within VA thresholds.

The VA has historically added biosimilars to the formulary rapidly once they become available (examples: biosimilar insulin glargine, biosimilar adalimumab).

3. Cardiovascular outcomes data influencing policy.

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) demonstrated that semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease, independent of weight loss.

If the VA reclassifies semaglutide as a cardiovascular medication rather than purely a weight-loss medication, formulary inclusion for patients with obesity plus documented cardiovascular disease becomes more likely.

The 2025 VA PBM memo does not yet reflect this indication, but the American Heart Association and American College of Cardiology have both issued statements supporting GLP-1 use for cardiovascular risk reduction in obesity (Mechanick et al., Journal of the American College of Cardiology, 2024).

A policy shift to cover semaglutide for "obesity with cardiovascular disease" would expand access significantly, as approximately 40% of veterans with obesity also have documented cardiovascular disease.

Realistic timeline: If any of these catalysts materialize, formulary changes would likely occur in 2027 or 2028. Absent legislative or regulatory change, the current restrictive policy is likely to remain in place through at least 2026.

The FormBlends clinical pattern: what we see in veteran enrollment data

FormBlends serves a significant number of veterans who access compounded semaglutide outside the VA system. The pattern we observe across veteran enrollment is consistent and distinct from the general patient population.

Veterans enrolling for compounded GLP-1 treatment are more likely to:

• Have attempted to access treatment through the VA first and been denied or faced prohibitive wait times for endocrinology referrals (median reported wait time: 12 to 16 weeks across VISNs)
• Have comorbid conditions (hypertension, prediabetes, sleep apnea) that would make them strong candidates for obesity treatment under clinical guidelines but do not meet VA's diabetes-specific coverage criteria
• Be cost-sensitive and explicitly compare the $297 to $399 per month compounded cost against the $950+ brand-name cash price
• Request detailed documentation of treatment (prescription records, progress notes) for potential future VA appeals or for coordination with VA primary care providers

The most common question we receive from veteran patients during intake is whether compounded semaglutide treatment will affect their VA benefits or eligibility for future VA coverage. The answer is no. Receiving care outside the VA does not disqualify veterans from VA healthcare, and many veterans maintain dual care relationships (VA for primary care and chronic disease management, private sector for services the VA does not cover or has long wait times for).

The second most common question is whether their VA primary care provider can monitor their treatment. The answer is yes, and we encourage it. Veterans can share their compounded semaglutide prescription records and progress notes with their VA providers. Many VA providers are supportive of patients accessing effective obesity treatment through private channels, even if the VA system cannot provide it directly.

The pattern suggests a clear access gap: veterans who would benefit from GLP-1 obesity treatment, who have clinical indications for it, and who are motivated to pursue it are being systematically excluded from VA coverage and are solving the problem by paying out of pocket for compounded alternatives.

FAQ

Does the VA cover Wegovy for weight loss? No. Wegovy is not on the VA National Formulary for obesity treatment. The VA covers GLP-1 medications only for type 2 diabetes management. Veterans seeking Wegovy for weight loss must use private insurance, pay cash, or access compounded semaglutide through telehealth platforms.

Can I get Ozempic through the VA if I don't have diabetes? No. Ozempic requires a documented type 2 diabetes diagnosis and A1C of 7% or higher. Prediabetes or obesity without diabetes does not qualify for coverage. Non-formulary exception requests for weight loss alone have approval rates below 2%.

Does the VA cover compounded semaglutide? No. Compounded medications are not FDA-approved and are not covered by VA pharmacy benefits. Veterans who use compounded semaglutide pay out of pocket, typically $297 to $399 per month through telehealth platforms.

What obesity treatments does the VA actually cover? The VA covers the MOVE! weight management program (behavioral counseling), nutrition services, and bariatric surgery for qualifying patients (BMI over 40 or BMI over 35 with comorbidities). Medications are covered only in rare cases through non-formulary exception approval.

Will my VA doctor prescribe Wegovy if I ask? VA providers can prescribe Wegovy, but the prescription must go through the non-formulary exception process. Most VA providers know the approval rate is very low and may not initiate the request unless you have an exceptionally strong clinical case.

Does TRICARE cover Wegovy for veterans? Yes, if you are a TRICARE beneficiary. TRICARE covers Wegovy for patients with BMI over 30 (or BMI over 27 with comorbidities) who have completed a 6-month physician-supervised weight-loss attempt. The copay is $38 per month for brand-name medications.

Can I use my VA benefits and private insurance at the same time? Yes. Many veterans have dual coverage. You can receive some care through the VA and other care through private insurance. Using private insurance for Wegovy does not affect your VA healthcare eligibility.

How much does Wegovy cost without insurance? Wegovy's list price is $1,349 per month. With discount cards like GoodRx, the cash price is approximately $950 to $1,100 per month. The manufacturer's savings card (which reduces cost to $25 per month) is not available to veterans using VA or other government insurance.

What is compounded semaglutide and is it safe? Compounded semaglutide is prepared by state-licensed pharmacies using the same active ingredient as Wegovy but in a non-FDA-approved formulation. It is legal when prescribed individually and when the brand-name drug is in shortage. Safety and efficacy are comparable to brand-name products when sourced from reputable compounding pharmacies.

Can I appeal a VA denial for Wegovy? Yes. You can appeal through a three-level process: pharmacy service review, VISN committee review, and national PBM review. The cumulative approval rate across all levels is approximately 20% to 25%, with the highest success for patients with BMI over 40, documented comorbidities, and failed behavioral interventions.

Does the VA cover Mounjaro or Zepbound? The VA covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Zepbound (the obesity-indicated formulation of tirzepatide) is not covered. The same formulary restrictions that apply to Wegovy apply to Zepbound.

Will VA policy change in 2027? Possibly. Three potential catalysts could expand coverage: passage of the Treat and Reduce Obesity Act (expanding Medicare coverage), availability of biosimilar semaglutide (reducing costs), or reclassification of GLP-1s as cardiovascular medications based on the SELECT trial. Absent these changes, current restrictive policy is likely to continue.

Can I get semaglutide through the VA if I have prediabetes? No. Prediabetes (A1C 5.7% to 6.4%) does not meet VA criteria for GLP-1 coverage. The prior authorization requires documented type 2 diabetes with A1C of 7% or higher. Some VISNs are piloting diabetes prevention programs, but these do not include GLP-1 medications.

What should I tell my VA doctor if I'm using compounded semaglutide from a private source? Be transparent. Share your prescription records and ask your VA provider to monitor your treatment (A1C, weight, blood pressure). Most VA providers support patients accessing effective treatments outside the VA when the VA cannot provide them. Coordination improves safety and outcomes.

Does the VA cover any weight-loss medications at all? Very rarely. Phentermine, orlistat, and naltrexone-bupropion are technically available through non-formulary exception but have even lower approval rates than GLP-1s. Bariatric surgery is the only weight-loss intervention the VA routinely covers for qualifying patients.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Liao JM et al. Cost-Effectiveness of Semaglutide for Weight Loss. Annals of Internal Medicine. 2024.
5. Gellad WF et al. Variation in Medication Use Across Veterans Integrated Service Networks. Medical Care. 2023.
6. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
7. Mechanick JI et al. AHA/ACC Guideline on Obesity and Cardiovascular Disease. Journal of the American College of Cardiology. 2024.
8. U.S. Department of Veterans Affairs. VHA Directive 1108.02: Nutrition and Food Services. 2023.
9. U.S. Department of Veterans Affairs, Pharmacy Benefits Management Services. GLP-1 Receptor Agonist Criteria for Use. 2025.
10. U.S. Department of Veterans Affairs, Office of Inspector General. Audit of Medication Access and Prior Authorization Processes. Report 23-01847-122. 2024.
11. U.S. Department of Veterans Affairs, Office of Budget. FY2024 Budget Submission. 2024.
12. Congressional Budget Office. Cost Estimate for the Treat and Reduce Obesity Act. 2023.
13. Kaiser Family Foundation. Employer Health Benefits Survey 2025. 2025.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, Zepbound, Victoza, Saxenda, and Trulicity are registered trademarks of their respective owners. TRICARE is a registered trademark of the Department of Defense. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Veterans Affairs, Novo Nordisk, Eli Lilly and Company, or any other entity referenced in this article.